human
coronavirus
hcov
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
novel
coronaviru
also
known
lead
global
epidem
high
morbid
mortal
howev
current
effect
drug
target
drug
repurpos
repres
effect
drug
discoveri
strategi
exist
drug
could
shorten
time
reduc
cost
compar
de
novo
drug
discoveri
studi
present
integr
antivir
drug
repurpos
methodolog
implement
system
pharmacologybas
network
medicin
platform
quantifi
interplay
hcovhost
interactom
drug
target
human
proteinprotein
interact
network
phylogenet
analys
hcov
whole
genom
reveal
share
highest
nucleotid
sequenc
ident
sarscov
specif
envelop
nucleocapsid
protein
two
evolutionarili
conserv
region
sequenc
ident
respect
compar
sarscov
use
network
proxim
analys
drug
target
hcovhost
interact
human
interactom
priorit
potenti
antihcov
repurpos
drug
eg
melatonin
mercaptopurin
sirolimu
valid
enrich
analys
druggen
signatur
hcovinduc
transcriptom
data
human
cell
line
identifi
three
potenti
drug
combin
eg
sirolimu
plu
dactinomycin
mercaptopurin
plu
melatonin
toremifen
plu
emodin
captur
complementari
exposur
pattern
target
drug
hit
hcovhost
subnetwork
target
separ
neighborhood
human
interactom
network
summari
studi
offer
power
networkbas
methodolog
rapid
identif
candid
repurpos
drug
potenti
drug
combin
target
coronavirus
cov
typic
affect
respiratori
tract
mammal
includ
human
lead
mild
sever
respiratori
tract
infect
past
two
decad
two
highli
pathogen
human
cov
hcov
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
anim
reservoir
led
global
epidem
high
morbid
mortal
exampl
individu
infect
die
sarscov
pandem
cost
global
economi
estim
billion
accord
world
health
organ
novemb
merscov
total
diagnos
case
caus
death
major
saudi
arabia
decemb
third
pathogen
hcov
name
novel
coronaviru
caus
coronaviru
diseas
abbrevi
covid
found
wuhan
china
februari
case
death
outbreak
worldwid
furthermor
humantohuman
transmiss
occur
among
close
contact
howev
current
effect
medic
sever
nation
intern
research
group
work
develop
vaccin
prevent
treat
effect
vaccin
avail
yet
urgent
need
develop
effect
prevent
treatment
strategi
outbreak
although
invest
biomed
pharmaceut
research
develop
increas
significantli
past
two
decad
annual
number
new
treatment
approv
us
food
drug
administr
fda
remain
rel
constant
limit
recent
studi
estim
pharmaceut
compani
spent
billion
million
develop
fdaapprov
new
chemic
entiti
drug
drug
repurpos
repres
effect
drug
discoveri
strategi
exist
drug
could
significantli
shorten
time
reduc
cost
compar
de
novo
drug
discoveri
random
clinic
trial
howev
experiment
approach
drug
repurpos
costli
timeconsum
comput
approach
offer
novel
testabl
hypothes
systemat
drug
reposit
howev
tradit
structurebas
method
limit
threedimension
structur
protein
unavail
unfortun
case
major
human
viral
target
addit
target
singl
viru
protein
often
high
risk
drug
resist
rapid
evolut
viru
genom
virus
includ
hcov
requir
host
cellular
factor
success
replic
infect
systemat
identif
virushost
proteinprotein
interact
ppi
offer
effect
way
toward
elucid
mechan
viral
infect
subsequ
target
cellular
antivir
target
virushost
interactom
may
offer
novel
strategi
develop
effect
treatment
viral
infect
includ
sarscov
merscov
ebola
viru
zika
viru
recent
present
integr
antivir
drug
discoveri
pipelin
incorpor
genetrap
insert
mutagenesi
known
function
druggen
network
bioinformat
analys
methodolog
allow
identifi
sever
candid
repurpos
drug
ebola
viru
work
last
decad
demonstr
network
strategi
exampl
use
identifi
effect
repurpos
drug
drug
combin
multipl
human
diseas
exampl
networkbas
drugdiseas
proxim
shed
light
relationship
drug
eg
drug
target
diseas
modul
molecular
determin
diseas
pathobiolog
modul
within
ppi
serv
use
tool
effici
screen
potenti
new
indic
approv
drug
well
drug
combin
demonstr
recent
studi
studi
present
integr
antivir
drug
repurpos
methodolog
combin
system
pharmacologybas
network
medicin
platform
quantifi
interplay
virushost
interactom
drug
target
human
ppi
network
basi
experi
rest
notion
protein
function
associ
viral
infect
includ
hcov
local
correspond
subnetwork
within
comprehens
human
ppi
network
ii
protein
serv
drug
target
specif
diseas
may
also
suitabl
drug
target
potenti
antivir
infect
owe
common
ppi
function
pathway
elucid
human
interactom
fig
follow
analysi
bioinformat
valid
druginduc
gene
signatur
hcovinduc
transcriptom
human
cell
line
inspect
postul
mechanismofact
specif
hcov
propos
repurpos
fig
date
seven
pathogen
hcov
fig
b
found
sarscov
merscov
genera
ii
genera
perform
phylogenet
analys
use
wholegenom
sequenc
data
hcov
inspect
evolutionari
relationship
hcov
found
whole
genom
nucleotid
sequenc
ident
across
three
diagnos
patient
supplementari
tabl
share
highest
nucleotid
sequenc
ident
sarscov
among
six
known
pathogen
hcov
reveal
conserv
evolutionari
relationship
sarscov
fig
hcov
five
major
protein
region
viru
structur
assembl
viral
replic
includ
replicas
complex
spike
envelop
e
membran
nucleocapsid
n
protein
fig
gene
encod
nonstructur
protein
nsp
viral
rna
synthesi
complex
proteolyt
process
viral
rnadepend
rna
polymeras
togeth
cofactor
possess
high
polymeras
activ
protein
structur
view
sarscov
contain
larger
ntermin
extens
bind
polymeras
domain
fig
spike
transmembran
glycoprotein
play
pivot
role
mediat
viral
infect
bind
host
receptor
figur
show
structur
spike
protein
bound
host
receptor
angiotensin
convert
sarscov
pdb
id
recent
studi
show
abl
util
entri
receptor
cell
suggest
potenti
drug
target
therapeut
develop
furthermor
cryoem
structur
spike
biophys
assay
reveal
spike
bind
higher
affin
sarscov
addit
nucleocapsid
also
import
subunit
packag
viral
genom
protein
oligomer
singl
nucleocapsid
structur
shown
fig
protein
sequenc
align
analys
indic
evolutionarili
conserv
sarscov
supplementari
tabl
specif
envelop
nucleocapsid
protein
two
evolutionarili
conserv
region
sequenc
ident
respect
compar
sarscov
supplementari
tabl
howev
spike
protein
exhibit
lowest
sequenc
conserv
sequenc
ident
sarscov
meanwhil
spike
protein
sequenc
ident
compar
merscov
fig
overal
workflow
studi
networkbas
methodolog
combin
system
pharmacologybas
network
medicin
platform
quantifi
interplay
virushost
interactom
drug
target
human
ppi
network
human
coronaviru
hcov
associ
host
protein
collect
literatur
pool
gener
panhcov
protein
subnetwork
b
network
proxim
drug
target
hcovassoci
protein
calcul
screen
candid
repurpos
drug
hcov
human
protein
interactom
model
c
gene
set
enrich
analysi
util
valid
networkbas
predict
e
top
candid
priorit
drug
combin
use
networkbas
method
captur
complementari
exposur
pattern
target
drug
hit
hcovhost
subnetwork
target
separ
neighborhood
human
interactom
network
f
overal
hypothesi
networkbas
methodolog
protein
function
associ
hcov
local
correspond
subnetwork
within
comprehens
human
interactom
network
ii
protein
serv
drug
target
specif
diseas
may
also
suitabl
drug
target
potenti
antivir
infect
owe
common
proteinprotein
interact
elucid
human
interactom
depict
hcovhost
interactom
network
assembl
covassoci
host
protein
four
known
hcov
sarscov
merscov
one
mous
mhv
one
avian
ibv
n
protein
supplementari
tabl
total
obtain
host
protein
associ
cov
variou
experiment
evid
specif
host
protein
either
direct
target
hcov
protein
involv
crucial
pathway
hcov
infect
hcovhost
interactom
network
shown
fig
identifi
sever
hub
protein
includ
jun
highest
number
connect
within
protein
kegg
pathway
enrich
analysi
reveal
multipl
signific
biolog
pathway
adjust
p
valu
includ
measl
rna
transport
nfkappa
b
signal
epsteinbarr
viru
infect
influenza
fig
gene
ontolog
go
biolog
process
enrich
analysi
confirm
multipl
viral
infectionrel
process
adjust
p
valu
includ
viral
life
cycl
modul
viru
host
morpholog
physiolog
viral
process
posit
regul
viral
life
cycl
transport
viru
virion
attach
host
cell
fig
map
known
drugtarget
network
see
materi
method
hcovhost
interactom
search
druggabl
cellular
target
found
human
protein
blue
node
fig
target
least
one
approv
drug
experiment
drug
clinic
trial
exampl
ikbkb
target
protein
high
druggabl
hcovhost
interactom
motiv
us
develop
drug
repurpos
strategi
specif
target
cellular
protein
associ
hcov
potenti
treatment
basi
propos
networkbas
drug
repurpos
methodolog
rest
notion
protein
associ
function
govern
viral
infect
local
correspond
subnetwork
fig
within
comprehens
human
interactom
network
drug
multipl
target
effect
hcov
target
protein
within
immedi
vicin
correspond
subnetwork
human
proteinprotein
interactom
fig
demonstr
multipl
diseas
use
networkbas
strategi
use
stateoftheart
network
proxim
measur
quantifi
relationship
hcovspecif
subnetwork
fig
drug
target
human
interactom
construct
drugtarget
network
assembl
target
inform
fdaapprov
experiment
drug
see
materi
method
improv
qualiti
complet
human
protein
interactom
network
integr
ppi
five
type
experiment
data
binari
ppi
protein
structur
binari
ppi
unbias
highthroughput
yeasttwohybrid
assay
experiment
identifi
kinasesubstr
interact
signal
network
deriv
experiment
data
literaturederiv
ppi
variou
experiment
evid
see
materi
method
use
zscore
z
measur
permut
test
reduc
studi
bia
network
proxim
analys
includ
hub
node
human
interactom
network
literaturederiv
ppi
data
bia
describ
recent
studi
total
comput
identifi
drug
associ
z
p
permut
test
hcovhost
interactom
fig
supplementari
tabl
valid
bia
pool
cellular
protein
six
cov
calcul
network
proxim
drug
four
cov
larg
number
know
host
protein
includ
sarscov
merscov
ibv
mhv
separ
found
zscore
show
consist
among
pool
hcovassoci
protein
four
individu
cov
fig
pearson
correl
coeffici
proxim
drug
pool
hcov
vs
sarscov
p
distribut
vs
merscov
p
vs
ibv
p
vs
mhv
p
network
proxim
analys
offer
put
repurpos
candid
potenti
prevent
treatment
hcov
valid
repurpos
drug
hcov
first
perform
gene
set
enrich
analysi
gsea
use
transcriptom
data
merscov
sarscov
infect
host
cell
see
method
transcriptom
data
use
gene
signatur
hcov
addit
download
gene
express
data
drugtreat
human
cell
line
connect
map
cmap
databas
obtain
druggen
signatur
calcul
gsea
score
see
method
drug
use
score
indic
bioinformat
valid
drug
specif
enrich
score
es
calcul
hcov
data
set
es
p
permut
test
use
cutoff
signific
associ
gene
signatur
drug
specif
hcov
data
set
gsea
score
rang
number
data
set
met
criteria
specif
drug
mesalazin
fig
discov
drughcov
network
subnetwork
highlight
networkpredict
drughcov
associ
connect
drug
hcov
drug
evalu
one
achiev
signific
proxim
drug
target
hcovassoci
protein
human
interactom
network
drug
color
firstlevel
anatom
therapeut
chemic
atc
classif
system
code
b
heatmap
highlight
network
proxim
valu
sarscov
merscov
ibv
mhv
respect
color
key
denot
network
proxim
zscore
drug
target
hcovassoci
protein
human
interactom
network
p
valu
comput
permut
test
approv
drug
inflammatori
bowel
diseas
sirolimu
approv
immunosuppress
drug
equilin
approv
agonist
estrogen
receptor
menopaus
symptom
achiev
highest
gsea
score
follow
paroxetin
melatonin
gsea
score
next
select
highconfid
repurpos
drug
fig
tabl
hcov
use
subject
matter
expertis
base
combin
factor
strength
networkpredict
associ
smaller
network
proxim
score
supplementari
tabl
ii
valid
gsea
analys
iii
literaturereport
antivir
evid
iv
fewer
clinic
report
side
effect
specif
showcas
sever
select
repurpos
drug
literaturereport
antivir
evid
overexpress
estrogen
receptor
shown
play
crucial
role
inhibit
viral
replic
select
estrogen
receptor
modul
serm
report
play
broader
role
inhibit
viral
replic
nonclass
pathway
associ
estrogen
receptor
serm
interfer
post
viral
entri
step
affect
trigger
fusion
serm
antivir
activ
still
observ
absenc
detect
estrogen
receptor
express
toremifen
z
fig
first
gener
nonsteroid
serm
exhibit
potenti
effect
block
variou
viral
infect
includ
merscov
sarscov
ebola
viru
establish
cell
line
compar
classic
antivir
pathway
toremifen
prevent
fusion
viral
endosom
membran
interact
destabil
viru
membran
glycoprotein
eventu
inhibit
viral
replic
shown
fig
toremifen
potenti
affect
sever
key
host
protein
associ
hcov
equilin
z
gsea
score
estrogen
steroid
produc
hors
also
proven
moder
activ
inhibit
entri
zair
ebola
viru
glycoprotein
human
immunodefici
viru
zebovgphiv
altogeth
networkpredict
serm
toremifen
equilin
offer
candid
repurpos
drug
angiotensin
receptor
blocker
arb
report
associ
viral
infect
includ
hcov
irbesartan
z
typic
arb
approv
fda
treatment
hypertens
diabet
nephropathi
network
proxim
analysi
show
signific
associ
irbesartan
target
hcovassoci
host
protein
human
interactom
shown
fig
irbesartan
target
encod
sodiumbil
acid
cotransport
ntcp
protein
identifi
function
receptor
hepat
b
viru
hbv
hepat
delta
viru
hdv
irbesartan
inhibit
ntcp
thu
inhibit
viral
entri
interact
potenti
transcript
repressor
interact
sarscov
sever
arb
eletriptan
frovatriptan
zolmitriptan
target
potenti
associ
hcovassoci
host
protein
human
interactom
previou
studi
confirm
mammalian
target
rapamycin
complex
key
factor
regul
variou
virus
replic
includ
and
orthohantaviru
coronaviru
sirolimu
z
gsea
score
inhibitor
mammalian
target
rapamycin
mtor
report
effect
block
viral
protein
express
virion
releas
effect
inde
latest
studi
reveal
clinic
applic
sirolimu
reduc
merscov
infect
moreov
sirolimu
usag
manag
patient
sever
pneumonia
acut
respiratori
failur
improv
patient
prognosi
significantli
mercaptopurin
z
gsea
score
antineoplast
agent
immunosuppress
properti
use
treat
cancer
sinc
expand
applic
sever
autoimmun
diseas
includ
rheumatoid
arthriti
system
lupu
erythematosu
crohn
diseas
see
figur
previou
page
fig
discov
drugproteinhcov
network
candid
repurpos
drug
networkpredict
evid
gene
set
enrich
analysi
gsea
score
potenti
repurpos
drug
hcov
overal
connect
top
drug
candid
hcovassoci
protein
examin
drug
indirectli
target
hcovassoci
protein
via
human
proteinprotein
interact
network
drugtargethcovassoci
protein
connect
examin
protein
least
five
connect
shown
box
height
protein
indic
number
connect
gsea
score
eight
drug
avail
na
due
lack
transcriptom
profil
drug
infer
mechanismofact
network
four
select
drug
b
toremifen
firstgener
nonsteroidalselect
estrogen
receptor
modul
c
irbesartan
angiotensin
receptor
blocker
mercaptopurin
antimetabolit
antineoplast
agent
immunosuppress
properti
e
melatonin
biogen
amin
treat
circadian
rhythm
sleep
disord
mechanist
mercaptopurin
potenti
target
sever
host
protein
hcov
jun
ncl
fig
inflammatori
pathway
play
essenti
role
viral
infect
biogen
amin
melatonin
z
gsea
score
play
key
role
variou
biolog
process
offer
potenti
strategi
manag
viral
infect
viral
infect
often
associ
immuneinflammatori
injuri
level
oxid
stress
increas
significantli
leav
neg
effect
function
multipl
organ
antioxid
effect
melatonin
make
put
candid
drug
reliev
patient
clinic
symptom
antivir
treatment
even
though
melatonin
erad
even
curb
viral
replic
transcript
addit
applic
melatonin
may
prolong
patient
surviv
time
may
provid
chanc
patient
immun
system
recov
eventu
erad
viru
shown
fig
melatonin
indirectli
target
sever
hcov
cellular
target
includ
jun
ikbkb
eplerenon
z
aldosteron
receptor
antagonist
report
similar
antiinflammatori
effect
melatonin
inhibit
mastcellderiv
proteinas
suppress
fibrosi
eplerenon
improv
surviv
mice
infect
encephalomyocard
viru
summari
network
proxim
analys
offer
multipl
candid
repurpos
drug
target
divers
cellular
pathway
potenti
prevent
treatment
howev
preclin
experi
clinic
trial
requir
verifi
clinic
benefit
networkpredict
candid
clinic
use
drug
combin
offer
increas
therapeut
efficaci
reduc
toxic
play
import
role
treat
variou
viral
infect
howev
abil
identifi
valid
effect
combin
limit
combinatori
explos
driven
larg
number
drug
pair
dosag
combin
recent
studi
propos
novel
networkbas
methodolog
identifi
clinic
efficaci
drug
combin
reli
approv
drug
combin
hypertens
cancer
found
drug
combin
therapeut
effect
captur
complementari
exposur
pattern
target
drug
hit
diseas
modul
target
separ
neighborhood
fig
sought
identifi
drug
combin
may
provid
synergist
effect
potenti
treat
welldefin
mechanismofact
network
analysi
potenti
repurpos
drug
fig
tabl
showcas
three
networkpredict
candid
drug
combin
predict
possibl
combin
found
supplementari
tabl
sirolimu
inhibitor
mtor
antifung
antineoplast
properti
demonstr
improv
outcom
patient
sever
pneumonia
acut
respiratori
failur
mtor
signal
play
essenti
role
merscov
infect
dactinomycin
also
known
actinomycin
approv
rna
synthesi
inhibitor
treatment
variou
cancer
type
earli
studi
show
dactinomycin
inhibit
growth
felin
enter
cov
shown
fig
network
analysi
show
sirolimu
dactinomycin
synergist
target
hcovassoci
host
protein
subnetwork
complementari
exposur
pattern
offer
potenti
combin
regimen
treatment
hcov
specif
sirolimu
dactinomycin
may
inhibit
mtor
signal
rna
synthesi
pathway
includ
dna
topoisomeras
dna
topoisomeras
hcovinfect
cell
fig
toremifen
among
approv
firstgener
nonsteroid
serm
treatment
metastat
breast
cancer
serm
includ
toremifen
inhibit
ebola
viru
infect
interact
destabil
ebola
viru
glycoprotein
vitro
assay
demonstr
toremifen
inhibit
growth
merscov
saracov
tabl
emodin
anthraquinon
deriv
extract
root
rheum
tanguticum
report
variou
antiviru
effect
specif
emdoin
inhibit
sarscovassoci
protein
block
interact
sarscov
spike
protein
ref
altogeth
network
analys
publish
experiment
data
suggest
combin
toremifen
emdoin
offer
potenti
therapeut
approach
fig
shown
fig
target
mercaptopurin
melatonin
show
strong
network
proxim
hcovassoci
host
protein
human
interactom
network
recent
vitro
vivo
studi
identifi
mercaptopurin
select
inhibitor
sarscov
merscov
target
papainlik
proteas
melatonin
report
potenti
antivir
infect
via
antiinflammatori
antioxid
effect
melatonin
indirectli
regul
express
key
entri
receptor
involv
viral
infect
hcov
includ
ref
specif
melatonin
report
inhibit
calmodulin
calmodulin
interact
inhibit
shed
ectodomain
key
infecti
process
sarscov
jun
also
known
cjun
key
host
protein
involv
hcov
infecti
bronchiti
viru
shown
fig
mercaptopurin
melatonin
may
synergist
block
cjun
signal
target
multipl
cellular
target
summari
combin
mercaptopurin
melatonin
may
offer
potenti
combin
therapi
synergist
target
papainlik
proteas
cjun
signal
antiinflammatori
pathway
fig
howev
experiment
observ
pathway
melatonin
highli
warrant
studi
present
networkbas
methodolog
systemat
identif
put
repurpos
drug
drug
combin
potenti
treatment
integr
drugtarget
network
hcovhost
interact
hcovinduc
transcriptom
human
cell
line
human
proteinprotein
interactom
network
essenti
identif
base
comprehens
evalu
priorit
candid
repurpos
drug
fig
potenti
drug
combin
fig
target
howev
although
major
predict
valid
variou
literatur
data
tabl
networkpredict
repurpos
drug
drug
combin
must
valid
variou
experiment
assay
random
clinic
trial
use
patient
acknowledg
sever
limit
current
studi
although
share
high
nucleotid
sequenc
ident
hcov
fig
predict
specif
lack
known
host
protein
use
low
bind
affin
valu
threshold
defin
physic
drugtarget
interact
howev
stronger
bind
affin
threshold
eg
may
suitabl
cutoff
drug
discoveri
although
gener
smaller
drugtarget
network
although
sizeabl
effort
made
assembl
larg
scale
experiment
report
drugtarget
network
publicli
avail
databas
network
data
may
incomplet
drugtarget
interact
may
function
associ
instead
physic
bind
exampl
silvestrol
natur
product
flavaglin
found
antivir
activ
ebola
coronavirus
ad
target
rna
helicas
enzym
silvestrol
predict
significantli
associ
hcov
z
p
network
proxim
analysi
increas
coverag
drugtarget
network
may
use
comput
approach
systemat
predict
drugtarget
interact
addit
collect
virushost
interact
far
complet
qualiti
influenc
multipl
factor
includ
differ
experiment
assay
human
cell
line
model
may
comput
predict
new
virushost
interactom
use
sequencebas
structurebas
approach
drug
target
repres
node
within
cellular
network
often
intrins
coupl
therapeut
advers
profil
drug
inhibit
activ
protein
function
includ
antagonist
vs
agonist
current
system
pharmacolog
model
separ
therapeut
antivir
effect
predict
due
lack
detail
pharmacolog
effect
drug
target
unknown
function
consequ
virushost
interact
comprehens
identif
virushost
interactom
specif
biolog
effect
use
function
genom
assay
significantli
improv
accuraci
propos
networkbas
methodolog
owe
lack
complet
drugtarget
inform
molecular
promiscu
drug
doserespons
dosetox
effect
see
figur
previou
page
fig
networkbas
ration
design
drug
combin
possibl
exposur
mode
hcovassoci
protein
modul
pairwis
drug
combin
effect
drug
combin
captur
complementari
exposur
pattern
target
drug
hit
hcovhost
subnetwork
target
separ
neighborhood
human
interactom
network
z
ca
z
cb
denot
network
proxim
zscore
target
drug
b
specif
hcov
ab
denot
separ
score
see
materi
method
target
drug
drug
b
bd
infer
mechanismofact
network
three
select
pairwis
drug
combin
b
sirolimu
potent
immunosuppress
antifung
antineoplast
properti
plu
dactinomycin
rna
synthesi
inhibitor
treatment
variou
tumor
c
toremifen
firstgener
nonsteroidalselect
estrogen
receptor
modul
plu
emodin
experiment
drug
treatment
polycyst
kidney
melatonin
biogen
amin
treat
circadian
rhythm
sleep
disord
plu
mercaptopurin
antimetabolit
antineoplast
agent
immunosuppress
properti
repurpos
drug
drug
combin
identifi
current
network
model
exampl
mesalazin
approv
drug
inflammatori
bowel
diseas
top
networkpredict
repurpos
drug
associ
hcov
fig
yet
sever
clinic
studi
show
potenti
pulmonari
toxic
includ
pneumonia
associ
mesalazin
usag
integr
lungspecif
gene
express
host
protein
physiolog
base
pharmacokinet
model
may
reduc
side
effect
repurpos
drug
drug
combin
preclin
studi
warrant
evalu
vivo
effici
side
effect
clinic
trial
furthermor
limit
predict
pairwis
drug
combin
base
previou
networkbas
framework
howev
expect
methodolog
remain
use
networkbas
tool
predict
combin
multipl
drug
toward
explor
network
relationship
multipl
drug
target
hcovhost
subnetwork
human
interactom
final
aim
systemat
identifi
repurpos
drug
specif
target
ncov
host
protein
thu
current
network
model
predict
repurpos
drug
exist
antiviru
drug
target
viru
protein
thu
combin
exist
antiviru
drug
remdesivir
networkpredict
repurpos
drug
fig
drug
combin
fig
may
improv
coverag
current
networkbas
methodolog
util
multilay
network
framework
conclus
studi
offer
power
integr
networkbas
system
pharmacolog
methodolog
rapid
identif
repurpos
drug
drug
combin
potenti
treatment
approach
minim
translat
gap
preclin
test
result
clinic
outcom
signific
problem
rapid
develop
effici
treatment
strategi
emerg
outbreak
translat
perspect
broadli
appli
network
tool
develop
could
help
develop
effect
treatment
strategi
emerg
viral
infect
human
complex
diseas
well
total
collect
dna
sequenc
protein
sequenc
hcov
includ
three
recent
genom
ncbi
genbank
databas
januari
supplementari
tabl
wholegenom
align
protein
sequenc
ident
calcul
perform
multipl
sequenc
align
emblebi
databas
http
wwwebiacuk
default
paramet
neighbor
join
nj
tree
comput
pairwis
phylogenet
distanc
matrix
use
mega
x
bootstrap
replic
protein
align
phylogenet
tree
hcov
construct
mega
x
collect
hcovhost
protein
interact
variou
literatur
base
sizeabl
effort
hcovassoci
host
protein
sever
hcov
includ
sarscov
merscov
ibv
mhv
pool
protein
either
direct
target
hcov
protein
involv
critic
pathway
hcov
infect
identifi
multipl
experiment
sourc
includ
highthroughput
yeasttwohybrid
system
viral
protein
pulldown
assay
vitro
coimmunoprecipit
rna
knock
experi
total
virushost
interact
network
includ
hcov
host
protein
supplementari
tabl
next
perform
kyoto
encyclopedia
gene
genom
kegg
gene
ontolog
go
enrich
analys
evalu
biolog
relev
function
pathway
hcovassoci
protein
function
analys
perform
use
enrichr
collect
drugtarget
interact
inform
drugbank
databas
therapeut
target
databas
ttd
pharmgkb
databas
chembl
bindingdb
iupharbp
guid
pharmacolog
chemic
structur
drug
smile
format
extract
drugbank
drugtarget
interact
meet
follow
three
criteria
use
bind
affin
includ
k
k
ic
ec
ii
target
mark
review
uniprot
databas
iii
human
target
repres
uniqu
uniprot
access
number
detail
build
experiment
valid
drugtarget
network
provid
recent
studi
build
comprehens
list
human
ppi
assembl
data
total
bioinformat
system
biolog
databas
five
type
experiment
evid
binari
ppi
test
highthroughput
yeasttwohybrid
system
ii
binari
physic
ppi
protein
structur
iii
kinasesubstr
interact
literaturederiv
lowthroughput
highthroughput
experi
iv
signal
network
literaturederiv
lowthroughput
experi
v
literaturecur
ppi
identifi
affin
purif
follow
mass
spectrometri
apm
literaturederiv
lowthroughput
experi
infer
data
includ
evolutionari
analysi
gene
express
data
metabol
associ
exclud
gene
map
entrez
id
base
ncbi
databas
well
offici
gene
symbol
base
genecard
http
wwwgenecardsorg
total
result
human
proteinprotein
interactom
use
studi
includ
uniqu
ppi
edg
link
connect
protein
node
repres
increas
number
ppi
use
previous
detail
descript
build
human
proteinprotein
interactom
provid
previou
studi
posit
human
ppi
provid
unbias
ration
roadmap
repurpos
drug
potenti
treatment
hcov
origin
approv
given
c
set
host
gene
associ
specif
hcov
set
drug
target
comput
network
proxim
c
target
set
drug
use
closest
method
c
shortest
distanc
gene
c
human
protein
interactom
network
proxim
convert
zscore
base
permut
test
r
r
mean
standard
deviat
permut
test
repeat
time
time
two
randomli
select
gene
list
similar
degre
distribut
c
correspond
p
valu
calcul
base
permut
test
result
zscore
p
consid
significantli
proxim
drughcov
associ
network
visual
use
gephi
http
gephiorg
networkbas
approach
drug
combin
effect
need
establish
topolog
relationship
two
drugtarget
modul
reflect
biolog
pharmacolog
relationship
also
quantifi
networkbas
relationship
drug
target
hcovassoci
host
protein
drugdrughcov
combin
identifi
potenti
drug
combin
combin
top
list
drug
separ
measur
ab
calcul
pair
drug
b
use
follow
method
h
calcul
base
closest
method
key
methodolog
drug
combin
therapeut
effect
follow
specif
relationship
diseas
modul
captur
complementari
exposur
pattern
target
modul
drug
without
overlap
toxic
mechan
perform
gene
set
enrich
analysi
addit
priorit
method
first
collect
three
differenti
gene
express
data
set
host
infect
hcov
ncbi
gene
express
omnibu
geo
among
two
transcriptom
data
set
sarscovinfect
sampl
patient
peripher
blood
cell
respect
one
transcriptom
data
set
merscovinfect
cell
adjust
p
valu
less
defin
differenti
express
gene
data
set
use
hcovhost
signatur
evalu
treatment
effect
drug
differenti
gene
express
cell
treat
variou
drug
retriev
connect
map
cmap
databas
use
gene
profil
drug
drug
cmap
data
set
drugtarget
network
calcul
enrich
score
es
hcov
signatur
data
set
base
previous
describ
method
j
gene
hcov
signatur
data
set
sort
ascend
order
rank
gene
profil
drug
evalu
rank
gene
j
denot
v
j
v
j
r
r
number
gene
drug
profil
es
updown
set
updown
updown
b
updown
set
updown
b
updown
updown
permut
test
repeat
time
use
randomli
gener
gene
list
number
upand
downregul
gene
hcov
signatur
data
set
perform
measur
signific
es
score
drug
consid
potenti
treatment
effect
es
p
number
hcov
signatur
data
set
use
final
gsea
score
rang
